Logos Global Management’s Astria Therapeutics ATXS Stock Holding History

Logos Global Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-500,000	Closed	-$3.64M	–	73
2025 Q3	$3.64M	Sell	500,000 -200,000	-29%	-$1.35M	0.33%	50
2025 Q2	$3.75M	Buy	700,000 +200,000	+40%	+$969K	0.42%	45
2025 Q1	$2.67M	Hold	500,000	–	–	0.47%	32
2024 Q4	$4.47M	Hold	500,000	–	–	0.52%	37
2024 Q3	$5.5M	Hold	500,000	–	–	0.59%	38
2024 Q2	$4.55M	Sell	500,000 -744,960	-60%	-$7.27M	0.37%	46
2024 Q1	$17.5M	Buy	1,244,960 +700,000	+128%	+$8.72M	1.42%	23
2023 Q4	$4.19M	Hold	544,960	–	–	0.39%	46
2023 Q3	$4.07M	Hold	544,960	–	–	0.54%	43
2023 Q2	$4.54M	Sell	544,960 -500,000	-48%	-$5.77M	0.62%	43
2023 Q1	$13.9M	Buy	1,044,960 +180,000	+21%	+$2.43M	1.99%	21
2022 Q4	$12.9M	Buy	+864,960	New	+$8.92M	1.51%	23
2021 Q3	–	Sell	-531,667	Closed	-$6.73M	–	60
2021 Q2	$6.73M	Buy	+531,667	New	+$6.9M	0.57%	43

Other funds holding ATXS

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Logos Global Management's ATXS Position: Q4 2025 in Review

Logos Global Management sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 500,000 shares — an estimated $3.64M sold.

Logos Global Management first reported a position in ATXS in Q2 2021 and held it in 13 quarters. The position peaked at $17.5M in Q1 2024. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

Logos Global Management reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
Logos Global Management sold 500,000 Astria Therapeutics shares in Q4 2025, an estimated $3.64M.
Logos Global Management first reported a position in Astria Therapeutics in Q2 2021 and held it in 13 quarters.
Logos Global Management's Astria Therapeutics position peaked at $17.5M in Q1 2024.
141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Logos Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.